Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
Biochim Biophys Acta ; 1446(3): 286-94, 1999 Sep 03.
Article in English | MEDLINE | ID: mdl-10524203

ABSTRACT

Mutations of the MEN1 tumor suppressor gene cause the multiple endocrine neoplasia type 1 (MEN1) syndrome in humans, and they are involved in a variety of sporadic human endocrine tumors. We here characterize the MEN1 gene homologs of the mouse and rat. cDNA was isolated from a mouse phage library, and two alternative MEN1 mRNA transcripts containing variant 5' untranslated regions were identified by RT-PCR in several mouse and rat tissues. When compared to the human molecule, mouse and rat MEN1 (611 and 610 amino acids, respectively) show an overall identity of 96.5% and 97.0% at the protein level, delimiting four conservational domains (A-D). Mouse and rat MEN1 mRNA, as studied by template-calibrated quantitative RT-PCR, is non-exclusively expressed in hematopoietic and endocrine cells, with similar expression patterns found in fetal and adult tissues. Fluorescent in situ hybridization maps the single murine MEN1 locus to chromosome 19, region B. No MEN1 gene mutations were identified in endocrine islet tumor cell lines RIN 5AH (rat) and NIT-1 (mouse) as compared to wild type cDNA. Our data define mouse and rat MEN1 as widely expressed and highly conserved homologs of the human MEN1 tumor suppressor gene whose role in biology and endocrine tumorigenesis is due for experimental study.


Subject(s)
Genes, Tumor Suppressor , Multiple Endocrine Neoplasia Type 1/genetics , Transcription Factors , Animals , Chromosome Mapping , DNA Probes , DNA, Complementary/chemistry , Gene Expression Regulation , Humans , In Situ Hybridization, Fluorescence , Mice , Molecular Sequence Data , Peptide Library , RNA, Messenger/analysis , RNA, Messenger/biosynthesis , Rats , Rats, Wistar , Reverse Transcriptase Polymerase Chain Reaction , Sequence Homology, Nucleic Acid , Tumor Cells, Cultured
2.
J Mol Biol ; 202(3): 397-406, 1988 Aug 05.
Article in English | MEDLINE | ID: mdl-2845099

ABSTRACT

Saturation mutagenesis of Tn10-encoded tet operator O1 was performed by chemical synthesis of 30 sequence variants yielding all possible point mutations of an operator half side. Their effect on Tet repressor binding was scored by an in-vivo repressor titration system. Tet repressor affinities of selected operator mutants were further characterized in vitro by dissociation rate measurements. The O1 sequence spans 19 base-pairs. Out of these, all 18 palindromic base-pairs are involved in Tet repressor recognition. The central base-pair does not contribute to sequence-specific binding of Tet repressor. At position 1 a pyrimidine residue is sufficient for maximal affinity to the repressor. At positions 2, 3 and 4, each mutation reduces repressor binding at least tenfold. Mutations at positions 5, 6, 7, 8 and 9 result in less drastic reductions of Tet repressor binding. Differential effects of mutations at a given position are used to deduce the chemical functions contacted by Tet repressor. The T.A to A.T transversion at position 9 increases Tet repressor affinity slightly, while all other mutations decrease repressor binding. The increased affinity of the wild-type tet operator O2 compared to wild-type O1 results from the addition of two favorable transversions at positions +/- 9 and an unfavorable T.A to C.G transition at position -7. Deletion or palindromic doubling of the central base-pair of the O1 palindrome reveals that the wild-type spacing of both operator half sides is crucial for efficient Tet repressor binding.


Subject(s)
Mutation , Operator Regions, Genetic , Repressor Proteins/genetics , Transcription Factors/genetics , Base Sequence , DNA Transposable Elements , DNA, Bacterial , Escherichia coli/genetics , Molecular Sequence Data
3.
Genetics ; 156(4): 1671-89, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11102366

ABSTRACT

let-502 rho-binding kinase and mel-11 myosin phosphatase regulate Caenorhabditis elegans embryonic morphogenesis. Genetic analysis presented here establishes the following modes of let-502 action: (i) loss of only maternal let-502 results in abnormal early cleavages, (ii) loss of both zygotic and maternal let-502 causes elongation defects, and (iii) loss of only zygotic let-502 results in sterility. The morphogenetic function of let-502 and mel-11 is apparently redundant with another pathway since elimination of these two genes resulted in progeny that underwent near-normal elongation. Triple mutant analysis indicated that unc-73 (Rho/Rac guanine exchange factor) and mlc-4 (myosin light chain) act in parallel to or downstream of let-502/mel-11. In contrast mig-2 (Rho/Rac), daf-2 (insulin receptor), and age-1 (PI3 kinase) act within the let-502/mel-11 pathway. Mutations in the sex-determination gene fem-2, which encodes a PP2c phosphatase (unrelated to the MEL-11 phosphatase), enhanced mutations of let-502 and suppressed those of mel-11. fem-2's elongation function appears to be independent of its role in sexual identity since the sex-determination genes fem-1, fem-3, tra-1, and tra-3 had no effect on mel-11 or let-502. By itself, fem-2 affects morphogenesis with low penetrance. fem-2 blocked the near-normal elongation of let-502; mel-11 indicating that fem-2 acts in a parallel elongation pathway. The action of two redundant pathways likely ensures accurate elongation of the C. elegans embryo.


Subject(s)
Caenorhabditis elegans Proteins , Caenorhabditis elegans/embryology , Helminth Proteins/physiology , Phosphoprotein Phosphatases/physiology , Protein Serine-Threonine Kinases/physiology , Receptor, Insulin/physiology , Amino Acid Sequence , Animals , Caenorhabditis elegans/enzymology , Caenorhabditis elegans/genetics , Contractile Proteins/genetics , Contractile Proteins/physiology , Disorders of Sex Development , Embryo, Nonmammalian/enzymology , Fertility , Helminth Proteins/genetics , Humans , Intracellular Signaling Peptides and Proteins , Molecular Sequence Data , Morphogenesis , Myosin-Light-Chain Phosphatase , Phenotype , Phosphoprotein Phosphatases/genetics , Protein Serine-Threonine Kinases/genetics , Receptor, Insulin/genetics , Sequence Alignment , Sequence Homology, Amino Acid , Sex Determination Processes , rho-Associated Kinases
4.
Genetics ; 128(2): 225-32, 1991 Jun.
Article in English | MEDLINE | ID: mdl-1649065

ABSTRACT

We have constructed a genetic assay which selects positively for a functional interaction between Tet repressor and its cognate operator in Escherichia coli. In this strain Tet repressor blocks expression of lacI and lacZ. This leads to derepression of a lacPO controlled galK gene. The strain can be selected by growth on galactose as the sole carbon source and screened for the beta-galactosidase phenotype. These features allow the identification of one candidate among 10(8) false clones on a single plate. The assay was applied to select mutants with a ts DNA binding phenotype and to screen oligonucleotide generated Tet repressor mutants. Analysis of these mutations revealed that they affect DNA and inducer binding and possibly the dimerization domains. These mutations are located at residues 21, 48, 49, 89 and at the C terminus of the protein (193), respectively.


Subject(s)
Bacterial Proteins/metabolism , DNA Transposable Elements , Escherichia coli/genetics , Operator Regions, Genetic , Repressor Proteins/metabolism , Amino Acid Sequence , Bacterial Proteins/genetics , Base Sequence , Cloning, Molecular , DNA, Bacterial , Molecular Sequence Data , Mutagenesis , Plasmids , Repressor Proteins/genetics , Temperature
5.
J Endocrinol ; 166(1): 1-9, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10856877

ABSTRACT

Germ line mutations of the multiple endocrine neoplasia type 1 (MEN1) tumour suppressor gene cause MEN1, a rare familial tumour syndrome associated with parathyroid hyperplasia, adenoma and hyperparathyroidism (HP). Here we investigated the role of the MEN1 gene in isolated sporadic and familial HP. Using RT-PCR single-strand conformational polymorphism screening, somatic (but not germ line) mutations of the MEN1 coding sequence were identified in 6 of 31 (19.3%) adenomas from patients with sporadic primary HP, but none in patients (n=16) with secondary HP due to chronic renal failure. MEN1 mutations were accompanied by a loss of heterozygosity (LOH) for the MEN1 locus on chromosome 11q13 in the adenomas as detected by microsatellite analysis. No DNA sequence divergence within the 5' region of the MEN1 gene, containing the putative MEN1 promoter, was detectable in HP adenomas. Clinical characteristics were not different in HP patients with or without MEN1 mutation. Heterozygous MEN1 gene polymorphisms were identified in 9.6% and 25% of patients with primary and secondary HP respectively. In a large kindred with familial isolated familial HP, MEN1 germ line mutation 249 del4 and LOH was associated with the HP phenotype and a predisposition to non-endocrine malignancies. We suggest that the bi-allelic somatic loss of MEN1 wild-type gene expression is involved in the pathogenesis of a clinically yet undefined subset of sporadic primary HP adenomas. MEN1 genotyping may further help define the familial hyperparathyroidism-MEN1 disease complex, but it seems dispensable in sporadic primary HP.


Subject(s)
Adenoma/genetics , Genes, Tumor Suppressor , Hyperparathyroidism/genetics , Multiple Endocrine Neoplasia Type 1/genetics , Parathyroid Neoplasms/genetics , Adult , Aged , Chromosomes, Human, Pair 11 , Female , Germ-Line Mutation , Humans , Loss of Heterozygosity , Male , Middle Aged , Polymorphism, Genetic , Polymorphism, Single-Stranded Conformational , Promoter Regions, Genetic , Reverse Transcriptase Polymerase Chain Reaction
6.
Neuroscience ; 169(1): 463-74, 2010 Aug 11.
Article in English | MEDLINE | ID: mdl-20417692

ABSTRACT

Bone-cancer-related pain is one of the most disabling factors in patients suffering from primary bone cancer or bone metastases. Recent studies point toward an important role of proinflammatory cytokines, example tumor necrosis factor-alpha (TNF), for tumor growth and bone-cancer-associated pain. Mechanisms by which TNF, through its receptor subtypes, TNF receptor 1 (TNFR1) and -2 (TNFR2), elicits altered sensation and pain behavior, are still incompletely understood. To look for a potential role of TNF in bone cancer pain, cancer-related pain was analyzed in fibrosarcoma-bearing C57Bl/6J wild type mice after systemic antagonism of TNF. To further clarify the role of TNF receptor (TNFR) in bone-cancer pain, naive and fibrosarcoma-bearing C57Bl/ 6J wild type and transgenic mice with a deficiency of TNFR1 (TNFR1ko), TNFR2 (TNFR2ko), and TNFR1+2 (TNFR1+2ko) were compared regarding cancer-related pain and hyperalgesia, tumor growth, osteoclast activation, and spinal astrogliosis. Systemic antagonism of TNF significantly alleviated tactile hypersensitivity and spontaneous bone-cancer-related pain behavior. Most interestingly, combined deletion of the TNFR1 and TNFR2, but not of either gene alone, almost completely inhibited the development of tactile hypersensitivity, whereas spontaneous pain behavior was transiently increased. Accordingly, spinal astrogliosis was markedly reduced, whereas tumor growth was significantly increased in TNFR1+2ko mice. In contrast, deletion of the TNFR1 or TNFR2 gene alone did not change tumor growth or spinal astrogliosis. Our findings suggest that the combined absence of TNFR1 and TNFR2 is necessary for the attenuation of cancer-related tactile hypersensitivity and concomitant spinal astrogliosis, whereas tumor growth seems to be inhibited by combined TNFR activation. These findings support the hypothesis of cytokine-dependent pain development in cancer pain. Differential targeting of TNFR activation could be an interesting strategy in bone-cancer-related pain conditions.


Subject(s)
Bone Neoplasms/secondary , Fibrosarcoma/secondary , Gliosis/physiopathology , Neoplasm Proteins/physiology , Pain/physiopathology , Receptors, Tumor Necrosis Factor, Type I/physiology , Receptors, Tumor Necrosis Factor/physiology , Spinal Cord/pathology , Tumor Necrosis Factor-alpha/physiology , Animals , Astrocytes/pathology , Behavior, Animal , Bone Neoplasms/physiopathology , Etanercept , Fibrosarcoma/physiopathology , Gliosis/etiology , Gliosis/prevention & control , Hyperalgesia/physiopathology , Hyperalgesia/prevention & control , Immunoglobulin G/pharmacology , Immunoglobulin G/therapeutic use , Lameness, Animal/etiology , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Osteoclasts/drug effects , Osteoclasts/pathology , Pain/etiology , Receptors, Tumor Necrosis Factor/deficiency , Receptors, Tumor Necrosis Factor/genetics , Receptors, Tumor Necrosis Factor/therapeutic use , Receptors, Tumor Necrosis Factor, Type I/deficiency , Receptors, Tumor Necrosis Factor, Type I/genetics , Touch , Tumor Necrosis Factor-alpha/antagonists & inhibitors
8.
Schmerz ; 21(5): 430-8, 2007 Oct.
Article in German | MEDLINE | ID: mdl-17323045

ABSTRACT

The aim of the present study was to develop a screening tool to aid non-headache specialists, like general practitioners, in deciding whether migraine prophylaxis in the individual migraine patient is useful or not. The first step was the development of a questionnaire, consisting of 10 items, which was filled in by 132 migraineurs who called on neurologists or headache experts. Independently, the physicians filled in another questionnaire to answer the question of whether they decided to prescribe migraine prophylaxis and if they had, to give their reasons for doing so. Using logistic regression analysis, we identified the three questions which had the most influence on the decision regarding prophylaxis in the data set. As results, we identified the following three questions: 1. Do you suffer from migraine on more than 3 days/month? 2. Do you have to rest in bed while experiencing a migraine attack? 3. Do you have to take medication against migraine on more than 5 days/month? Validation of this reduced questionnaire is currently ongoing and involves 150 migraine patients of general practitioners.


Subject(s)
Migraine Disorders/prevention & control , Humans , Prospective Studies , Reproducibility of Results , Surveys and Questionnaires , Time Factors
9.
Nucleic Acids Res ; 18(10): 2875-80, 1990 May 25.
Article in English | MEDLINE | ID: mdl-2161514

ABSTRACT

A saturating oligonucleotide-directed mutagenesis of both tet operators in the tet regulatory sequence was performed yielding mutants with four identical base pair exchanges at equivalent positions in the four tet operator half sides. The mutants were cloned between bipolar lacZ and galK indicator genes on a multicopy plasmid allowing the quantitative analysis of their effects in vivo. In the absence of Tet repressor the mutations lead to considerably different expression levels of both genes. They are discussed with respect to the promoter consensus sequences. In particular, the -10 region of the in vivo active tetPR2 promoter is unambiguously defined by these results. In the presence of Tet repressor most of the mutants exhibit a lower affinity for that protein as determined quantitatively by their reduced expression levels. In general, tet operator recognition is most strongly affected by alterations of base pairs near the center of the palindromic sequence. The most important position is the third base pair, followed by base pairs two, four, five and six, the latter showing similar effects as base pair one. At each position, the four possible base pairs show different affinities for Tet repressor. They are discussed according to their exposure of H-bond donors and -acceptors in the major and minor grooves of the B-DNA. The results are in agreement with major groove contacts at positions two, three and five. At position four a low potential correlation of efficiencies with the H-bonding in the minor groove is found, while mutations at position six seem to influence repressor binding by other mechanisms.


Subject(s)
Bacterial Proteins/metabolism , DNA Transposable Elements , Operator Regions, Genetic , Repressor Proteins/metabolism , Transcription Factors/metabolism , Base Sequence , Cloning, Molecular , Escherichia coli/genetics , Gene Expression Regulation, Bacterial , Molecular Sequence Data , Molecular Structure , Mutation , Promoter Regions, Genetic , Regulatory Sequences, Nucleic Acid
10.
Dev Biol ; 209(1): 111-27, 1999 May 01.
Article in English | MEDLINE | ID: mdl-10208747

ABSTRACT

Caenorhabditis elegans embryonic elongation is driven by cell shape changes that cause a contraction of the epidermal cell layer enclosing the embryo. We have previously shown that this process requires a Rho-associated kinase (LET-502) and is opposed by the activity of a myosin phosphatase regulatory subunit (MEL-11). We now extend our characterization and show that mel-11 activity is required both in the epidermis during embryonic elongation and in the spermatheca of the adult somatic gonad. let-502 and mel-11 reporter gene constructs show reciprocal expression patterns in the embryonic epidermis and the spermatheca, and mutations of the two genes have opposite effects in these two tissues. These results are consistent with let-502 and mel-11 mediating tissue contraction and relaxation, respectively. We also find that mel-11 embryonic inviability is genetically enhanced by mutations in a Rac signaling pathway, suggesting that Rac potentiates or acts in parallel with the activity of the myosin phosphatase complex. Since Rho has been implicated in promoting cellular contraction, our results support a mechanism by which epithelial morphogenesis is regulated by the counteracting activities of Rho and Rac.


Subject(s)
Caenorhabditis elegans Proteins , Caenorhabditis elegans/embryology , Caenorhabditis elegans/metabolism , Epidermis/embryology , Gonads/embryology , Helminth Proteins/physiology , Phosphoprotein Phosphatases/metabolism , Phosphoprotein Phosphatases/physiology , Protein Serine-Threonine Kinases/genetics , Animals , Blotting, Northern , Embryo, Nonmammalian/anatomy & histology , Female , Fetal Viability , GTP-Binding Proteins/metabolism , GTP-Binding Proteins/physiology , Gene Expression , Genotype , Green Fluorescent Proteins , Helminth Proteins/metabolism , Infertility , Intracellular Signaling Peptides and Proteins , Luminescent Proteins/metabolism , Models, Genetic , Mutagenesis , Myosin-Light-Chain Phosphatase , Nerve Tissue Proteins/metabolism , Oviducts/metabolism , Phenotype , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction , Temperature , Time Factors , Uterus/metabolism , rac GTP-Binding Proteins , rho-Associated Kinases
11.
Nucleic Acids Res ; 14(10): 4253-66, 1986 May 27.
Article in English | MEDLINE | ID: mdl-3086838

ABSTRACT

The effect of single base pair alterations of the Tn10 encoded tet operator on recognition of Tet repressor was studied in vivo using a repressor titration system and in vitro by dissociation rate determinations of the respective complexes. Both methods reveal that the two operators, O1 and O2, which are in a tandem arrangement in the wild type, are recognized with a two-fold different affinity when separated. Studies on synthetic operator sequences indicate that the Tet repressor binds with higher affinity to the non-palindromic O2 wildtype than to the respective palindromic sequences. The in vivo repressor titration system links the expression of lacZ to the affinity of tet operator to Tet repressor. It was used to isolate tet operator mutations with reduced affinity to the repressor. The in vivo and in vitro obtained results with these mutants agree quantitatively and indicate, that the GC base pairs at positions 2, 6, and 8 are involved in interaction with the Tet repressor. Their importance for recognition decreases in that order. Transitions at position 7 of the tet operator show smaller effects on recognition than transversions.


Subject(s)
Mutation , Operon , Repressor Proteins/genetics , Transcription Factors/genetics , Drug Resistance, Microbial , Escherichia coli/drug effects , Gene Expression Regulation , Hydroxylamine , Hydroxylamines/pharmacology , Phenotype , Plasmids , Structure-Activity Relationship , Tetracycline/pharmacology , beta-Galactosidase/analysis
12.
EMBO J ; 10(13): 4145-52, 1991 Dec.
Article in English | MEDLINE | ID: mdl-1756721

ABSTRACT

Each of 22 amino acids in the proposed alpha-helix-turn-alpha-helix operator binding motif of the Tn10 encoded Tet repressor was replaced by alanine and one residue was replaced by valine to determine their role in tet operator recognition by a 'loss of contact' analysis with 16 operator variants. One class of amino acids consisting of T27 and R28 in the first alpha-helix and L41, Y42, W43 and H44 in the recognition alpha-helix are quantitatively most important for wild-type operator binding. These residues are probably involved in the structural architecture of the motif. A second class of residues is quantitatively less important for binding, but determines specificity by forming base pair specific contacts to three positions in tet operator. This property is most clearly demonstrated for Q38 and P39 and to a lesser extent for T40 at the N-terminus of the recognition alpha-helix. The contacted operator base pairs indicate that the N-terminus of the recognition alpha-helix is located towards the palindromic center in the repressor-operator complex. Although the orientation of the recognition alpha-helix in the Tet repressor-tet operator complex is inversed as compared with the lambda- and 434 repressor-operator complexes, the reduced operator binding of the TA27 mutation in the first alpha-helix suggests that the hydrogen bonding networks connecting the two alpha-helices may be similar in these proteins.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Amino Acids/genetics , Operator Regions, Genetic , Repressor Proteins/genetics , Amino Acid Sequence , Base Sequence , Blotting, Western , DNA, Bacterial/metabolism , Escherichia coli/genetics , Molecular Sequence Data , Mutation , Plasmids , Protein Conformation , R Factors/genetics , Substrate Specificity
13.
Genes Dev ; 11(4): 409-22, 1997 Feb 15.
Article in English | MEDLINE | ID: mdl-9042856

ABSTRACT

We have identified two genes associated with the hypodermal cell shape changes that occur during elongation of the Caenorhabditis elegans embryo. The first gene, called let-502, encodes a protein with high similarity to Rho-binding Ser/Thr kinases and to human myotonic dystrophy kinase (DM-kinase). Strong mutations in let-502 block embryonic elongation, and let-502 reporter constructs are expressed in hypodermal cells at the elongation stage of development. The second gene, mel-11, was identified by mutations that act as extragenic suppressors of let-502. mel-11 encodes a protein similar to the 110- to 133-kD regulatory subunits of vertebrate smooth muscle myosin-associated phosphatase (PP-1M). We suggest that the LET-502 kinase and the MEL-11 phosphatase subunit act in a pathway linking a signal generated by the small GTP-binding protein Rho to a myosin-based hypodermal contractile system that drives embryonic elongation. LET-502 may directly regulate the activity of the MEL-11 containing phosphatase complex and the similarity between LET-502 and DM-kinase suggests a similar function for DM-kinase.


Subject(s)
Caenorhabditis elegans/genetics , Cell Size , Phosphoprotein Phosphatases/metabolism , Protein Serine-Threonine Kinases/genetics , Alleles , Amino Acid Sequence , Animals , Caenorhabditis elegans/cytology , Caenorhabditis elegans/embryology , Caenorhabditis elegans Proteins , Cloning, Molecular , GTP-Binding Proteins/metabolism , Gene Expression Regulation, Developmental , Genes, Suppressor , Humans , Intracellular Signaling Peptides and Proteins , Molecular Sequence Data , Myosin-Light-Chain Phosphatase , Myotonin-Protein Kinase , Protein Binding , Protein Serine-Threonine Kinases/metabolism , Sequence Homology, Amino Acid , rho-Associated Kinases
14.
Langenbecks Arch Surg ; 383(2): 183-6, 1998 Apr.
Article in English | MEDLINE | ID: mdl-9641896

ABSTRACT

INTRODUCTION: Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder characterized by the development of multiple endocrine adenomas, typically in the pancreas, anterior pituitary, and parathyroid glands. The disease is associated with germ-line mutations of the menin gene, a putative tumor-suppressor gene located on human chromosome 11q13. METHODS: To facilitate the diagnosis and prediction of MEN1 in patients and their relatives, we developed a molecular two-step strategy to screen for menin gene mutations. DNA fragments covering the entire menin coding sequence are generated from patient cDNA by polymerase reaction (PCR) and subsequently analyzed by single-strand conformational polymorphism electrophoresis (SSCP). Fragments with aberrant SSCP migration are DNA-sequenced to directly characterize menin mutations. In a second diagnostic step, genomic DNA of healthy relatives of the corresponding MEN1 index patient is analyzed by PCR, with only the specific exon amplified harboring the family-specific mutation. Mutation-specific restriction enzyme digestion of this PCR product finally allows the identification of mutation carriers through pathological restriction fragment patterns. RESULTS: Using this approach, we identified an in-frame deletion mutation (delta Tyr Met) located in menin exon 4 (codon 227-228) that co-segregates with the disease phenotype in a large MEN1 family from Southern Germany. CONCLUSION: It is likely that the direct molecular analysis of menin gene mutations will replace the genetic and biochemical screening tests currently used in the clinical management of MEN1 families. In addition, these studies may provide clues to the tumor biology of both sporadic and MEN1-associated endocrine adenomas.


Subject(s)
Multiple Endocrine Neoplasia Type 1/genetics , Mutation/genetics , Neoplasm Proteins/genetics , Proto-Oncogene Proteins , Adult , Chromosome Aberrations/genetics , Chromosome Deletion , Chromosome Disorders , Chromosomes, Human, Pair 11 , DNA Mutational Analysis , Female , Genes, Dominant/genetics , Genetic Carrier Screening , Genetic Testing , Humans , Male , Middle Aged , Multiple Endocrine Neoplasia Type 1/diagnosis , Multiple Endocrine Neoplasia Type 1/prevention & control , Pedigree , Polymerase Chain Reaction
15.
EMBO J ; 11(4): 1487-92, 1992 Apr.
Article in English | MEDLINE | ID: mdl-1563352

ABSTRACT

We have investigated whether the RNA polymerase III-driven transcription of eukaryotic tRNA genes can be regulated by the prokaryotic tetracycline operator-repressor system. The bacterial tet operator (tetO) was inserted at two different positions (-7 and -46) upstream of a tRNA(Glu) (amber) suppressor gene. Both constructs are transcribed in Saccharomyces cerevisiae and yield functional tRNAs as scored by suppression of an amber nonsense mutation in the met8-1 allele. Controlled expression of Tet repressor was achieved by fusing the bacterial tetR gene to the yeast gal1 promoter. This leads to expression of Tet repressor in yeast on galactose--but not on glucose--containing media. Regulation of the su-tRNA gene with the tetO fragment inserted at position -7 has been demonstrated. Under conditions which allow tetR expression, cells exhibit a met- phenotype. This methionine auxotrophy can be conditionally reverted to prototrophy by adding tetracycline. However, a su-tRNA gene with the tetO fragment inserted at position -46 cannot be repressed. Our results demonstrate clearly that the bacterial repressor protein binds to its operator in the yeast genome. Formation of this complex in the vicinity of the pol III transcription initiation site reduces the level of su-tRNA at least 50-fold as concluded from quantitative primer extension analyses. This indicates for the first time that class III gene expression can be regulated by a DNA binding protein with its target site in the 5'-flanking region and that a prokaryotic repressor can confer regulation of a suitably engineered tRNA gene.


Subject(s)
Gene Expression Regulation, Fungal , Genes, Bacterial , Genes, Suppressor , Operon , RNA Polymerase III/metabolism , RNA, Transfer, Glu/genetics , RNA, Transfer/genetics , Saccharomyces cerevisiae/genetics , Tetracycline/pharmacology , Transcription, Genetic , Alleles , Animals , Base Sequence , Cloning, Molecular , DNA-Binding Proteins/metabolism , Dictyostelium/genetics , Molecular Sequence Data , Phenotype , Plasmids , RNA, Transfer/isolation & purification , Restriction Mapping , Saccharomyces cerevisiae/drug effects , Saccharomyces cerevisiae/enzymology
SELECTION OF CITATIONS
SEARCH DETAIL